5PSQ-074 Activity of enzalutamide after abiraterone in castration-resistant prostate cancer

BACKGROUND: There is only limited information about the sequential use of abiraterone acetate (AA) and enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC) patients. Patients who receive AA or ENZ as first-line therapy and subsequently become resistant have only a response r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Hosp Pharm
Autors principals: Soto, A Alcalá, Moreno, R Gavira, Sánchez, JF Sierra, Pérez, A Varas, Pichardo, L Jiménez, Moreno, C Puivecino, Calvo, MT Gómez de Travecedo y
Format: Artigo
Idioma:Inglês
Publicat: BMJ Group 2018
Matèries:
Section 5: Patient safety and quality assurance
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535372/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.428
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars